Promising Obesity Drug Results
Viking Therapeutics reports positive trial results for its experimental obesity drug VK2735.
Anonymous
Key Points
1
During the initial 21-week induction period, VK2735 produced mean weight reductions of approximately 16% to 19%, compared with about 0% for placebo. Among treated participants, 65% achieved at least 15% weight loss and 32% achieved at least 20% weight loss.
2
Analysts at Oppenheimer said VK2735’s potential competitive advantage may depend less on initial weight loss alone and more on its “long-term persistence, flexibility, convenience and continuity of care.”
3
Viking is competing in an obesity-drug market dominated by Novo Nordisk and Eli Lilly; analysts cited in the report expect the market to reach $100 billion in annual sales by 2030.
4
A TipRanks AI assessment rated Viking’s stock Neutral, citing strong clinical momentum but also accelerating losses and cash burn, a negative price-to-earnings ratio, and shares trading below their 20-day average.
Viking Therapeutics reported strong results for VK2735, an experimental obesity drug that helps patients keep most of their weight loss even when they take injections less often. In a 12-week test, patients who switched from weekly shots to every-other-week dosing kept 97% of their weight loss, while those on monthly injections retained 90%, compared with just 61% for placebo RTTNews. The news sent Viking's stock soaring — shares jumped between 22% and 26% following the announcement TipRanks.
VK2735 is a dual GLP-1/GIP agonist, a newer class of obesity drug that acts on two hormones to control hunger and blood sugar. The drug showed no clear plateau in weight loss, with patients on 17.5 mg weekly achieving roughly 22% weight loss compared with placebo by Week 33 Endpoints News. Side effects and treatment dropouts stayed low and matched placebo levels, making it a potentially attractive option in a crowded market dominated by Novo Nordisk and Eli Lilly Prism Market View.
How VK2735 Stacks Up Against Placebo
During the initial 21-week phase, VK2735 delivered mean weight cuts of 16% to 19%, while placebo patients saw essentially no change Prism Market View. Two-thirds of treated patients hit at least 15% weight loss, and one-third achieved 20% or more. These numbers matter because they show the drug works right from the start, setting a strong baseline for the maintenance phase that followed Endpoints News.
Why Flexible Dosing Could Be a Game-Changer
The real win for Viking is showing that less frequent dosing doesn't mean losing progress. Analysts at Oppenheimer say VK2735's edge may rest not just on how much weight people lose upfront, but on "long-term persistence, flexibility, convenience and continuity of care." Endpoints News That matters because it's easier for patients to stick with a monthly shot than a weekly one, which could help people stay on the drug longer and boost sales.
An Expanding Market, But Rising Competition Looms
The obesity-drug market is expected to hit $100 billion in annual sales by 2030, according to analyst forecasts Prism Market View. Right now, Novo Nordisk and Eli Lilly dominate with their GLP-1 drugs Ozempic and Mounjaro. Viking's VK2735 — available as both injectable and oral forms — could carve out space if it proves as easy to use and effective as the data suggests. The company plans to test oral maintenance dosing next, offering even more convenience Yahoo Finance.
Stock Surge Tempered by Financial Caution From Analysts
While investors celebrated the VK2735 news, TipRanks AI analysts rated Viking's stock Neutral, citing strong clinical results but also warning of rising losses and cash burn. The company trades below its 20-day average price and has a negative price-to-earnings ratio, raising questions about when — or if — the drug will reach the market and turn a profit TipRanks. Strong trial data alone doesn't guarantee commercial success or financial stability.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
40
Articles
139
Reach
179
A
AnonymousAuthor
